YENOM NOTICIAS

Qué está moviendo el mercado.

Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.

IVBXF
Limpiar

Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.

finance.yahoo.comPOSITIVO

Top China Biopharma Stocks to Watch, According to Bernstein

Investing.com -- Bernstein has identified several China-based biopharmaceutical companies positioned to benefit from evolving drug development capabilities, with a focus on integrated platforms and service providers that support AI-enabled…

finance.yahoo.comPOSITIVO

Innovent Biologics (SEHK:1801) Stock Still Looks Below Fair Value As Shares Rose 153%

Innovent Biologics has delivered a very large 3 year share price return, which puts the current valuation firmly under the microscope for anyone focused on cash flows. With the stock recently closing at HK$95.90, the key issue is how that…

finance.yahoo.comPOSITIVO

2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Sept. 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative me…

finance.yahoo.comPOSITIVO

Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the tre…

finance.yahoo.comPOSITIVO

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs…

finance.yahoo.comNEGATIVO

Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting

SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the trea…

finance.yahoo.comPOSITIVO

Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market

SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Altruist Biologics, a world-class contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics (1801.HK), announced that its Suzhou commercial ma…

finance.yahoo.comPOSITIVO

Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA

Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from concept to potential commercialization. LP-003 is the first innovative drug independent…

finance.yahoo.comPOSITIVO

OPKO Health (OPK) Cashes In A Future Royalty Stream Early

On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 dr…

finance.yahoo.comPOSITIVO

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

Company Logo Complement Inhibitors MarketComplement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule…

finance.yahoo.comPOSITIVO

Which China stocks stand to win From the AI boom? UBS names its picks

Investing.com -- UBS reiterated an Attractive rating on Chinese equities and reshuffled its Greater China focus list, adding five names it believes are positioned for the country's AI build-out. "We retain our preference for China's tech s…

finance.yahoo.comPOSITIVO

Market Chatter: Novo Nordisk Reports China Regulators Accept Weight-Loss Drug Application

Novo Nordisk (NVO) said Thursday that China's National Medical Products Administration has accepted PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…

finance.yahoo.comPOSITIVO

Innovent Announces 2026 Interim Results and Business Updates

Transforming from Regional Leader to Global Premier: A Clear Strategic Path for Growth and Globalization SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopha…

finance.yahoo.comPOSITIVO

Does Daiichi Sankyo Company (TSE:4568) Have A Bigger Oncology Opening In China And Europe?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Daiichi Sankyo Company (TSE:4568) has signed an exclusive commercialization agreement with Innovent Biologics for acute myel…

finance.yahoo.comPOSITIVO

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

Spero Therapeutics, Inc. Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved Utebzi™ (tebip…

finance.yahoo.comPOSITIVO

Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China

Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Daiichi Sankyo (TSE: 4568), have…

finance.yahoo.comNEGATIVO

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal Cancer in China

SAN FRANCISCO and SUZHOU, China, Aug. 5, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treat…

nasdaq.comPOSITIVO

Innovent Grants Spero Ex-China Rights To Anti-CD40L Antibody IBI355 In Up To $1.1 Bln Deal

(RTTNews) - Innovent Biologics, Inc (IVBXF) said on Tuesday it entered into an exclusive licensing agreement with Spero Therapeutics, Inc. (SPRO) for IBI355, a third-generation Fc-silent anti-CD40L antibody being developed for autoimmune d…

finance.yahoo.comPOSITIVO

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001) Innovent will receive an upfront payment, and is eli…

finance.yahoo.comPOSITIVO

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Spero Therapeutics, Inc. Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, a…

finance.yahoo.comPOSITIVO

Innovent’s China Verzenios Deal and New Jaypirca Nod Might Change The Case For Investing In Eli Lilly (LLY)

In late June 2026, Innovent Biologics announced a distribution and promotion agreement giving it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, while Lilly retains manufacturing, supply and de…

finance.yahoo.comPOSITIVO

Eli Lilly (LLY) After The China Verzenios Shift And The Valuation Debate

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (LLY) is back in focus after handing Chinese partner Innovent Biologics full commercial c…

finance.yahoo.comPOSITIVO

Eli Lilly (LLY) Expands R And D Reach With Abbisko And China Drug Handover

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE:LLY) has entered a new research collaboration with Abbisko Cayman Limited, focused…

finance.yahoo.comPOSITIVO

Eli Lilly Hands China Sales Rights for Verzenio to Innovent

This article first appeared on GuruFocus. Eli Lilly (LLY, Financials) is turning to Innovent Biologics to handle sales of Verzenio in mainland China. The breast cancer drug has been available there since 2021. Last year, it generated about…

finance.yahoo.comPOSITIVO

Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China

SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the trea…

finance.yahoo.comPOSITIVO

Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026

Financing co-led by TCGX and ARCH Venture Partners with participation from a syndicate of premier healthcare-focused institutional investors Proceeds will support global Phase 3 trials of IBI324 (Ollin R&D code: OLN324), a potential best-i…

finance.yahoo.comPOSITIVO

Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, June 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treat…

finance.yahoo.comPOSITIVO

Novo Nordisk to File Oral Wegovy in China

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) rose 0.27% intraday after CEO Mike Doustdar told reporters the company plans to submit oral Wegovy for Chinese regulatory approval "very soon," estimating a timeline of "a f…

finance.yahoo.comPOSITIVO

Global Value Stocks Trading Below Estimated Worth In June 2026

As global markets navigate a landscape marked by inflation pressures, geopolitical tensions, and fluctuating energy prices, investors are increasingly seeking opportunities in undervalued stocks. In this environment of cautious optimism an…

finance.yahoo.comPOSITIVO

3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 29.4%

As global markets navigate through heightened inflation pressures and geopolitical tensions, Asian equities present a complex landscape with both challenges and opportunities. In this environment, identifying undervalued stocks can be part…

finance.yahoo.comPOSITIVO

2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline

SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatm…

finance.yahoo.comPOSITIVO

Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.

If you keep regular tabs on pharmaceutical giant Pfizer (NYSE: PFE), then you know it hasn't yet restored the revenue lost due to the wind-down of the COVID-19 pandemic; the world just doesn't need its vaccine (Comirnaty) or its infection…

finance.yahoo.comPOSITIVO

3 Asian Stocks Estimated To Be Priced Below Intrinsic Value In June 2026

As Asian markets navigate a complex landscape of geopolitical developments and economic indicators, investors are increasingly focused on identifying opportunities that may be priced below their intrinsic value. In this context, understand…

finance.yahoo.comPOSITIVO

3 Asian Stocks Estimated To Be Up To 43.2% Below Intrinsic Value

As global markets respond to geopolitical developments and economic indicators, Asian equities present intriguing opportunities, particularly in the context of fluctuating oil prices and AI-driven technological advancements. In this enviro…

finance.yahoo.comNEGATIVO

World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA

SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatm…

finance.yahoo.comPOSITIVO

Dark Horse Consulting Group and Altruist Biologics Announce Memorandum of Understanding to Advance Biologics Manufacturing and Development in China

Dark Horse Consulting Group WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biolo…